nemluvio™
(nemolizumab-ilto) for injection
30 mg

Identifying a List of Adults With Prurigo Nodularis (PN) Using a Topical Agent in the EMA® EHR System

IMPORTANT SAFETY INFORMATION

Indication: NEMLUVIO® is an interleukin-31 receptor antagonist indicated for the treatment of adults with prurigo nodularis. **Contraindication:** Known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO. **Warnings/Precautions:** Hypersensitivity reactions have been reported with NEMLUVIO use. If a clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO. **Adverse Events:** Most common adverse reactions (incidence ≥1%) are headache, dermatitis atopic, eczema, and eczema nummular.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit *www.fda.gov/medwatch* or call 1-800-FDA-1088.

Please see accompanying Prescribing Information or click here for full Prescribing Information.

EHR, electronic health record; EMA, Electronic Medical Assistant; FDA, U.S. Food and Drug Administration.

GALDERMA
EST. 1981

Overview and Limitations

nemluvio™
(nemolizumab-ilto) for injection
30 mg

This document provides health systems interested in updating their EHR systems with instructions to generate a list of patients with PN who may not be adequately responding to topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI). Once a patient list has been generated, patients can be reached through their preferred communication method via a letter, the patient portal, or the phone. These instructions are specific to Galderma and the EMA EHR system and are not appropriate for other conditions, treatments, and therapeutic areas or for other EHR systems.

The processes that follow are variable, and not all steps will apply to every health system. Any steps or settings that are not part of a health system's standard process should be excluded or modified accordingly. Any questions should be directed to the appropriate service provider. The system is solely responsible for implementing, testing, monitoring, and the ongoing operation of any EHR tools.

Considerations and Criteria

The clinical data elements provided are only suggestions; it is strongly recommended that clinical and operational leadership ensure that the final elements align with the expectations and goals of the organization.

Suggested criteria:

ICD-10 Diagnosis Code—see code below for PN.

Coding is a clinical decision; ensure you are coding to the highest level of specificity. The code shown below is only a suggestion and may vary by patient.

ICD-10 Code[1]	Description[1]
L28.1	Prurigo nodularis
L29.8	Other pruritus
L29.9	Pruritus, unspecified

AND

- Have been on one to two topicals (TCS/TCI)

EHR, electronic health record; EMA, Electronic Medical Assistant; ICD-10, International Classification of Diseases, Tenth Revision; PN, prurigo nodularis.

Please see Important Safety Information on page 1 and accompanying Prescribing Information or click here for full Prescribing Information.

Instructions

nemluvio™
(nemolizumab-ilto) for injection
30 mg

EMA has two reporting options— **Analytics** and the **Advanced Patient Search**.

The **Analytics** solution can create patient reports with multiple variables in a criterion. Use of the Analytics reporting tool may require access credentials, and some expertise with Analytics is helpful to run the patient query.

The **Advanced Patient Search** capability is limited to querying single-variable criteria, (e.g., a combination of a single ICD-10 code and a single medication). To find use of one or two topicals, the end user can manually swap the medication with another medication, a process that requires minimal time, but multiple searches are required.

The instructions for both reporting solutions are included below.

Analytics Instructions

1. From the home screen, select **Analytics**
2. Click **Financials** (the data may take a few minutes to load)
3. Click **Compliance Reports**
4. In the Production Data column, select the **Production Summary Custom** report
5. In the Posted Date filter, set the desired date range (restricting the date range may help to accelerate the runtime of the report and can be adjusted later)
6. From the **Dimensions**, select ICD-10, Patient Link, and NDC Description
7. From the **Measures**, select Patient Count
8. Click the spyglass in the ICD-10 column and enter and select the ICD-10 code for Prurigo Nodularis: L28.1. Add all rows with L28.1 (since many patients may have comorbid conditions). Repeat and add the Prurigo ICD-10 codes L29.8 and L29.9[1]
9. Click the spyglass in the NDC Description column and select the desired TCS and TCI from the list of available options. A search feature is available if needed
10. Click the download link to export the report and then click **Close**
11. Alternatively, click the Patient Link hyperlink to review the patient's information in the patient chart

EMA, Electronic Medical Assistant; ICD-10, International Classification of Diseases, Tenth Revision; NDC, National Drug Code; TCI, topical calcineurin inhibitors; TCS, topical corticosteroids.

Please see Important Safety Information on page 1 and accompanying Prescribing Information or click here for full Prescribing Information.

Instructions (cont'd)

nemluvio™ (nemolizumab-ilto) for injection 30 mg

Advanced Patient Search Instructions

1. From the home screen, select **Patients**
2. Click **Advanced Patient Search**
3. In the **Problem** field, enter the ICD-10 code for Prurigo Nodularis: L28.1[1]
4. In the **Medication** field, enter the desired TCS or TCI (only one medication can be entered per search query)
5. Click **Search** to run the patient query
6. To export the results, click the **Show > Hide > Save PDF** buttons to export the results
7. In the final Excel report, manipulate the filters to view all patients matching the criteria
8. To review all the medications the patient has tried, select the patient profile and review all medications in the patient chart
9. To find patients using other ICD-10 codes, change the ICD-10 codes (L29.8 and L29.9 in Step 3 above)[1]
10. To find patients using other TCS or TCI, change the medication in Step 4 above

ICD-10, International Classification of Diseases, Tenth Revision; TCI, topical calcineurin inhibitors; TCS, topical corticosteroids.

Please see Important Safety Information on page 1 and accompanying Prescribing Information or click here for full Prescribing Information.

Notes

nemluvio™
(nemolizumab-ilto) for injection
30 mg

- The customer (e.g., the medical group, IDN, organized customer group, and/or health system) shall be solely responsible for implementation, testing, and monitoring of the instructions to ensure proper orientation in each customer's EHR system

- Capabilities, functionality, and setup (customization) for each individual EHR system may vary. Galderma shall not be responsible for revising the implementation instructions it provides to any customer if the customer modifies or changes its software, or the configuration of its EHR system, after such time as the implementation instructions have been initially provided by Galderma

- While Galderma tests its implementation instructions on multiple EHR systems, the instructions are not guaranteed to work for all available EHR systems, and Galderma shall have no liability thereto

- While EHRs may assist providers in identifying potentially appropriate patients for consideration of assessment and treatment, the decision and action should ultimately be decided by a provider in consultation with the patient, after a review of the patient's records to determine appropriateness and eligibility, and Galderma shall have no liability thereto

- The instructions have not been designed for and are not tools and/or solutions for meeting Meaningful Use, Advancing Care Information, MACRA/MIPS Quality Measures, Quality Payment Program, and/or any other quality/accreditation requirement

- All products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Galderma and/or its affiliates

EHR, electronic health record; IDN, integrated delivery network; MACRA, Medicare Access and CHIP Reauthorization Act of 2015; MIPS, Merit-Based Incentive Payment System.

Reference: 1. Centers for Medicare & Medicaid Services. Accessed June 10, 2024. https://www.cms.gov/medicare/coding-billing/icd-10 codes/2024-icd-10-cm

Please see Important Safety Information on page 1 and accompanying Prescribing Information or click here for full Prescribing Information.

GALDERMA
EST. 1981